BioSpace News Archive

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, announced that members of its management team will participate in the following investor conferences,.

Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive results from the second preplanned interim analysis of its Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

Terns Pharmaceuticals, Inc. today announced the appointment of Emil Kuriakose, M.D. as chief medical officer of Terns oncology, effective May 1, 2023.

On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative molecular imaging (IMI) agents to target and illuminate cancer during surgery, today announced publication of results from the ELUCIDATE Phase 3 Trial of CYTALUX (pafolacianine) injection for use of IMI for cancer in the lung.

Aadi Bioscience, Inc. today announced the appointment of Mohammad Hirmand, M.D. to its Board of Directors.

Expanding Capacity to Deliver GMP Projects

Saranas, Inc. announced today that it has reached the midpoint for enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety of complex high-risk percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS).

OncoNano Medicine, Inc. presented data from a Phase 2 study of pegsitacianine, a pH-sensitive fluorescent nanoprobe for image-guided cancer surgery, at the Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care, occurring March 22-25 in Boston, MA.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that a respiratory patient monitoring program using data from Teva’s Digihaler System has been implemented within California’s Desert Oasis Healthcare system.

Delcath Systems, Inc. announced that the US Food and Drug Administration (FDA) has accepted Delcath Systems, Inc.'s (Delcath) new drug application resubmission for HEPZATO™ Kit.